GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Pozycja w akcjach
#3635
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Cena akcji
$27.54
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$4.67B
Zmiana (1 dzień)
-2.73%
Zmiana (1 rok)
-12.13%
Kraj
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategoria
Healthcare
Zyski dla GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Zyski w Jun 2026 TTM: $159.96M
Według najnowszych raportów finansowych GlaxoSmithKline Pharmaceuticals Limited, obecny zysk firmy wynosi $159.96M. W roku 2024 firma osiągnęła zysk w wysokości $97.88M, spadek w porównaniu do zysku z roku 2023, który wynosił $101.78M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy GlaxoSmithKline Pharmaceuticals Limited od 2004 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $159.96M | 8.59% |
| 2025 | $147.31M | 50.49% |
| 2024 | $97.88M | -3.82% |
| 2023 | $101.78M | -0.83% |
| 2022 | $102.63M | 65.48% |
| 2021 | $62.02M | 52.81% |
| 2020 | $40.59M | -58.72% |
| 2019 | $98.31M | 18.54% |
| 2018 | $82.93M | 5.21% |
| 2017 | $78.83M | -9.71% |
| 2016 | $87.30M | -9.89% |
| 2015 | $96.88M | -0.90% |
| 2013 | $97.77M | -35.64% |
| 2012 | $151.90M | -13.05% |
| 2011 | $174.69M | -10.43% |
| 2010 | $195.02M | 19.11% |
| 2009 | $163.74M | 13.31% |
| 2008 | $144.51M | -9.37% |
| 2007 | $159.46M | 24.82% |
| 2006 | $127.75M | 17.87% |
| 2005 | $108.38M | 10.05% |
| 2004 | $98.49M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $33.60B | 20,902.13% |
US
|
|
| $17.74B | 10,988.20% |
US
|
|
| $8.70B | 5,338.14% |
US
|
|
| $5.95B | 3,618.36% |
US
|
|
| $21.39B | 13,270.79% |
CH
|
